EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) Meeting Abstract
| Authors: | Bedke, J.; Powles, T.; Valderrama, B. P.; Gupta, S.; Kikuchi, E.; Loriot, Y.; Galsky, M D.; Sridhar, S. S.; Yu, E. Y.; Hoffman-Censits, J.; Iyer, G.; Castellano, D.; Maroto-Rey, P.; Mar, N.; Dawson, N. A.; Bavle, A.; Gorla, S. R.; Yu, X.; Lu, Y. T.; Van Der Heijden, M. S. |
| Abstract Title: | EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | 4571 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.4571 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4571 -- Source: Cinahl |
